Trial Profile
The Effect of Niacin Administration on Oxidative Stress in Patients With Hypercholesterolmia, as Measured by the Use of a Novel Biomarker.
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2020
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Hypercholesterolaemia; Low HDL cholesterol
- Focus Biomarker; Pharmacodynamics
- 25 Feb 2010 New trial record